The college of American pathologists' first 3 years' experience with high-risk human papillomavirus proficiency testing for cytology and other laboratories

Ann T. Moriarty, Joel S. Bentz, Barbara Winkler, Andrew H. Fischer, Rodolfo Laucirica, Rhona J. Souers, Nicole Thomas, Chengquan Zhao

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Context.- The College of American Pathologists (CAP) Human Papillomavirus (High-Risk) Survey for Cytopathology and Other Laboratories (CHPV) meets the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) requirements for 5 proficiency testing challenges analyzed 3 times per year. This study reports laboratory performance for CHPV from 2008 through 2010. Objective.- To identify trends in proficiency testing performance for subscribers to the CAP CHPV. Design.- CHPV responses were evaluated by using a nonlinear mixed model (significance level of .05) with a 2- factor interaction term and repeated measures component, comparing year, media, method, and intended response. Media types included Digene transport, SurePath, Thin- Prep media, or a mixture of media types. Proficiency testing challenges validated at 80% consensus. Results.- All challenges validated; 476 laboratories submitted 14 911 responses with 14 620 correct responses (98%). There were no differences between positive or negative challenges, or rate of correct responses; significant differences existed between media types by year and methods. Digene and ThinPrep media performed better than SurePath (P < .001; P=.03). There was a statistically significant difference between methods (P < .001); "other commercial kits," "other (noncommercial)" tests, and Third Wave performed more poorly than others. Conclusions.- Laboratories performed well when testing for human papillomavirus in CHPV during a period of 3 years. All challenges performed to the 80% threshold. Significant differences were found between methods and media. The CAP CHPV survey provides useful information for laboratories choosing human papillomavirus testing methods.

Original languageEnglish (US)
Pages (from-to)606-609
Number of pages4
JournalArchives of Pathology and Laboratory Medicine
Volume137
Issue number5
DOIs
StatePublished - May 1 2013

Fingerprint

Cell Biology
Nonlinear Dynamics
Pathologists
Surveys and Questionnaires

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

The college of American pathologists' first 3 years' experience with high-risk human papillomavirus proficiency testing for cytology and other laboratories. / Moriarty, Ann T.; Bentz, Joel S.; Winkler, Barbara; Fischer, Andrew H.; Laucirica, Rodolfo; Souers, Rhona J.; Thomas, Nicole; Zhao, Chengquan.

In: Archives of Pathology and Laboratory Medicine, Vol. 137, No. 5, 01.05.2013, p. 606-609.

Research output: Contribution to journalArticle

Moriarty, Ann T. ; Bentz, Joel S. ; Winkler, Barbara ; Fischer, Andrew H. ; Laucirica, Rodolfo ; Souers, Rhona J. ; Thomas, Nicole ; Zhao, Chengquan. / The college of American pathologists' first 3 years' experience with high-risk human papillomavirus proficiency testing for cytology and other laboratories. In: Archives of Pathology and Laboratory Medicine. 2013 ; Vol. 137, No. 5. pp. 606-609.
@article{93ca1342bb60470ea8fbdfb6d9c75e55,
title = "The college of American pathologists' first 3 years' experience with high-risk human papillomavirus proficiency testing for cytology and other laboratories",
abstract = "Context.- The College of American Pathologists (CAP) Human Papillomavirus (High-Risk) Survey for Cytopathology and Other Laboratories (CHPV) meets the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) requirements for 5 proficiency testing challenges analyzed 3 times per year. This study reports laboratory performance for CHPV from 2008 through 2010. Objective.- To identify trends in proficiency testing performance for subscribers to the CAP CHPV. Design.- CHPV responses were evaluated by using a nonlinear mixed model (significance level of .05) with a 2- factor interaction term and repeated measures component, comparing year, media, method, and intended response. Media types included Digene transport, SurePath, Thin- Prep media, or a mixture of media types. Proficiency testing challenges validated at 80{\%} consensus. Results.- All challenges validated; 476 laboratories submitted 14 911 responses with 14 620 correct responses (98{\%}). There were no differences between positive or negative challenges, or rate of correct responses; significant differences existed between media types by year and methods. Digene and ThinPrep media performed better than SurePath (P < .001; P=.03). There was a statistically significant difference between methods (P < .001); {"}other commercial kits,{"} {"}other (noncommercial){"} tests, and Third Wave performed more poorly than others. Conclusions.- Laboratories performed well when testing for human papillomavirus in CHPV during a period of 3 years. All challenges performed to the 80{\%} threshold. Significant differences were found between methods and media. The CAP CHPV survey provides useful information for laboratories choosing human papillomavirus testing methods.",
author = "Moriarty, {Ann T.} and Bentz, {Joel S.} and Barbara Winkler and Fischer, {Andrew H.} and Rodolfo Laucirica and Souers, {Rhona J.} and Nicole Thomas and Chengquan Zhao",
year = "2013",
month = "5",
day = "1",
doi = "10.5858/arpa.2012-0149-CP",
language = "English (US)",
volume = "137",
pages = "606--609",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "5",

}

TY - JOUR

T1 - The college of American pathologists' first 3 years' experience with high-risk human papillomavirus proficiency testing for cytology and other laboratories

AU - Moriarty, Ann T.

AU - Bentz, Joel S.

AU - Winkler, Barbara

AU - Fischer, Andrew H.

AU - Laucirica, Rodolfo

AU - Souers, Rhona J.

AU - Thomas, Nicole

AU - Zhao, Chengquan

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Context.- The College of American Pathologists (CAP) Human Papillomavirus (High-Risk) Survey for Cytopathology and Other Laboratories (CHPV) meets the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) requirements for 5 proficiency testing challenges analyzed 3 times per year. This study reports laboratory performance for CHPV from 2008 through 2010. Objective.- To identify trends in proficiency testing performance for subscribers to the CAP CHPV. Design.- CHPV responses were evaluated by using a nonlinear mixed model (significance level of .05) with a 2- factor interaction term and repeated measures component, comparing year, media, method, and intended response. Media types included Digene transport, SurePath, Thin- Prep media, or a mixture of media types. Proficiency testing challenges validated at 80% consensus. Results.- All challenges validated; 476 laboratories submitted 14 911 responses with 14 620 correct responses (98%). There were no differences between positive or negative challenges, or rate of correct responses; significant differences existed between media types by year and methods. Digene and ThinPrep media performed better than SurePath (P < .001; P=.03). There was a statistically significant difference between methods (P < .001); "other commercial kits," "other (noncommercial)" tests, and Third Wave performed more poorly than others. Conclusions.- Laboratories performed well when testing for human papillomavirus in CHPV during a period of 3 years. All challenges performed to the 80% threshold. Significant differences were found between methods and media. The CAP CHPV survey provides useful information for laboratories choosing human papillomavirus testing methods.

AB - Context.- The College of American Pathologists (CAP) Human Papillomavirus (High-Risk) Survey for Cytopathology and Other Laboratories (CHPV) meets the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) requirements for 5 proficiency testing challenges analyzed 3 times per year. This study reports laboratory performance for CHPV from 2008 through 2010. Objective.- To identify trends in proficiency testing performance for subscribers to the CAP CHPV. Design.- CHPV responses were evaluated by using a nonlinear mixed model (significance level of .05) with a 2- factor interaction term and repeated measures component, comparing year, media, method, and intended response. Media types included Digene transport, SurePath, Thin- Prep media, or a mixture of media types. Proficiency testing challenges validated at 80% consensus. Results.- All challenges validated; 476 laboratories submitted 14 911 responses with 14 620 correct responses (98%). There were no differences between positive or negative challenges, or rate of correct responses; significant differences existed between media types by year and methods. Digene and ThinPrep media performed better than SurePath (P < .001; P=.03). There was a statistically significant difference between methods (P < .001); "other commercial kits," "other (noncommercial)" tests, and Third Wave performed more poorly than others. Conclusions.- Laboratories performed well when testing for human papillomavirus in CHPV during a period of 3 years. All challenges performed to the 80% threshold. Significant differences were found between methods and media. The CAP CHPV survey provides useful information for laboratories choosing human papillomavirus testing methods.

UR - http://www.scopus.com/inward/record.url?scp=84877978282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877978282&partnerID=8YFLogxK

U2 - 10.5858/arpa.2012-0149-CP

DO - 10.5858/arpa.2012-0149-CP

M3 - Article

VL - 137

SP - 606

EP - 609

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 5

ER -